Amedeo Smart

Free Medical Literature Service

 

Amedeo

Pancreatitis
  Free Subscription

Articles published in
Gut
    July 2026
  1. LEE M, Yu MH, Chae W, Lee YH, et al
    Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study.
    Gut. 2026 Jul 24:gutjnl-2025-335863. doi: 10.1136/gutjnl-2025-335863.
    >> Share

  2. LIU W, Wang X, Chen R, Wen L, et al
    Neutrophil extracellular traps induced by tumour-derived NGAL reprogram CAF subtypes via ITGA5 to promote tumour progression in pancreatic cancer.
    Gut. 2026 Jul 16:gutjnl-2025-337720. doi: 10.1136/gutjnl-2025-337720.
    >> Share

  3. JIANG K, Lai CH, Dong S, Lee CP, et al
    Multimodal C9-66 CAR-T cell immunotherapy improves outcome in preclinical models of pancreatic cancer.
    Gut. 2026 Jul 15:gutjnl-2025-337545. doi: 10.1136/gutjnl-2025-337545.
    >> Share

  4. ALNATSHA A, Xu J, Habshi T, Li Q, et al
    Dysregulated sphingolipid metabolismdrives pancreatic carcinogenesis through plasma membrane Kras enrichment.
    Gut. 2026 Jul 3:gutjnl-2025-337363. doi: 10.1136/gutjnl-2025-337363.
    >> Share

  5. YU Z, Qing H, Wang T, Xing Z, et al
    USP20 promotes CD8(+) T cell exhaustion and impairs KRAS(G12D) inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer.
    Gut. 2026 Jul 2:gutjnl-2026-338277. doi: 10.1136/gutjnl-2026-338277.
    >> Share

    June 2026
  6. WU W
    Early high-energy enteral nutrition in acute pancreatitis: overfeeding and respiratory risk in high-risk patients.
    Gut. 2026 Jun 25:gutjnl-2026-339296. doi: 10.1136/gutjnl-2026-339296.
    >> Share

  7. STUPAKOV P, Sadatrezaei G, Velazquez Quesada I, Boe LA, et al
    Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism.
    Gut. 2026 Jun 23:gutjnl-2025-337316. doi: 10.1136/gutjnl-2025-337316.
    >> Share

  8. VAN DEN BOSSCHE JL, Van der Vliet M, Michiels E, Azurmendi Senar O, et al
    Luminal-basal stratification of the native human pancreatic duct is differentially represented in pancreatic cancers.
    Gut. 2026 Jun 4:gutjnl-2025-337970. doi: 10.1136/gutjnl-2025-337970.
    >> Share

  9. SHI L, Li W, Chen D, Liu B, et al
    TNF-alpha drives pancreatic microcirculatory dysfunction via CD8(+) T cell-mediated endothelial injury in severe acute pancreatitis.
    Gut. 2026 Jun 3:gutjnl-2025-337183. doi: 10.1136/gutjnl-2025-337183.
    >> Share

    May 2026
  10. TONG J, Wu JW, Zou WB, Mao XT, et al
    Physical activity reshapes intrapancreatic immune and inflammatory programmes to restrain chronic pancreatitis.
    Gut. 2026 May 28:gutjnl-2025-337862. doi: 10.1136/gutjnl-2025-337862.
    >> Share

  11. LUO Y, Yang J, Liu X, Zhang B, et al
    Tumour-infiltrating adipocyte-derived 12,13-DiHOME subverts CD8(+) T cell immunity in pancreatic ductal adenocarcinoma by promoting PPARgamma-mediated ferritinophagy and tumour-associated neutrophil ferroptosis.
    Gut. 2026 May 28:gutjnl-2025-337119. doi: 10.1136/gutjnl-2025-337119.
    >> Share

  12. MICHL P, Roth L
    Seeing the unseen: AI radiomics unmasking occult pancreatic cancer?
    Gut. 2026 May 8:gutjnl-2026-338712. doi: 10.1136/gutjnl-2026-338712.
    >> Share

    April 2026
  13. CAI G, Varadi A, Berchegyi M, Szalai EA, et al
    Low-enzyme acute pancreatitis-a diagnostic blind spot in current guidelines.
    Gut. 2026 Apr 28:gutjnl-2025-337992. doi: 10.1136/gutjnl-2025-337992.
    >> Share

  14. MUKHERJEE S, Antony A, Patnam NG, Trivedi KH, et al
    Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability.
    Gut. 2026 Apr 28:gutjnl-2025-337266. doi: 10.1136/gutjnl-2025-337266.
    >> Share

  15. CAO Y, Hu J, Ye J, Zou D, et al
    Circulating extracellular vesicle long RNA profiling combined with machine learning unveils novel diagnostic signature and molecular features in chronic pancreatitis.
    Gut. 2026 Apr 16:gutjnl-2025-335957. doi: 10.1136/gutjnl-2025-335957.
    >> Share

    March 2026
  16. LI J, Chen Y, Bai X, Feng Y, et al
    When a pancreatic pseudocyst is not a pseudocyst: diagnostic pitfalls and complications.
    Gut. 2026 Mar 18:gutjnl-2026-338333. doi: 10.1136/gutjnl-2026-338333.
    >> Share

  17. MARTA K, Engh MA, Vincze A, Eross B, et al
    High versus gradually increasing energy nutrition in the early phase of acute pancreatitis (GOULASH): a multicentre double-blind randomised clinical trial.
    Gut. 2026 Mar 5:gutjnl-2025-335970. doi: 10.1136/gutjnl-2025-335970.
    >> Share

  18. ZHANG J, Gu J, Wang X, Xia R, et al
    SLC6A14-mediated carnitine transmembrane uptake from PPARgamma(+) cancer-associated fibroblasts promotes recurrence of pancreatic cancer.
    Gut. 2026 Mar 5:gutjnl-2025-336116. doi: 10.1136/gutjnl-2025-336116.
    >> Share

  19. FORSMARK CE
    Are the drugs already on the shelf? Repurposing therapy for pancreatitis.
    Gut. 2026 Mar 3:gutjnl-2025-337879. doi: 10.1136/gutjnl-2025-337879.
    >> Share

    February 2026
  20. BAI B, Xiang W, Chen X, Chen Q, et al
    Oleic acid promotes lung injury in hypertriglyceridaemia-associated acute pancreatitis via the PIEZO1/NR4A1/CPT1A axis impairing endothelial fatty acid oxidation.
    Gut. 2026 Feb 19:gutjnl-2025-336441. doi: 10.1136/gutjnl-2025-336441.
    >> Share

  21. ZHOU T, Yan J, Zhang Y, Mao G, et al
    Trogocytosis-orchestrated CLDN18.2-"dressed" CD8(+) T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.
    Gut. 2026 Feb 10:gutjnl-2025-335790. doi: 10.1136/gutjnl-2025-335790.
    >> Share

  22. WANG R, Li J, Su D, Yang J, et al
    KRAS-driven protein disulfide isomerase family A member 6 expression suppresses PRKR-like endoplasmic reticulum kinase-mediated immunogenic cell death to desensitise pancreatic ductal adenocarcinoma to immune checkpoint blockers.
    Gut. 2026 Feb 10:gutjnl-2025-335641. doi: 10.1136/gutjnl-2025-335641.
    >> Share

  23. CHEN Y, Jin GW, He LH, Dong Y, et al
    MTFP1 drives pancreatic cancer liver metastatic colonisation by regulating mitochondrial metabolism reprogramming.
    Gut. 2026 Feb 9:gutjnl-2025-336323. doi: 10.1136/gutjnl-2025-336323.
    >> Share

  24. MOTA-PINO J, Fernandez-Capetillo O
    Exploiting a purine imbalance to target KRAS mutant pancreatic adenocarcinomas.
    Gut. 2026 Feb 4:gutjnl-2025-337940. doi: 10.1136/gutjnl-2025-337940.
    >> Share

    January 2026
  25. ESPOSITO I, Haeberle L, Luchini C
    From IPMN to invasive pancreatic cancer: new spatial insights.
    Gut. 2026 Jan 28:gutjnl-2025-337622. doi: 10.1136/gutjnl-2025-337622.
    >> Share

  26. ZENG L, Liu S, Peng X, Xue C, et al
    NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis.
    Gut. 2026 Jan 22:gutjnl-2025-336541. doi: 10.1136/gutjnl-2025-336541.
    >> Share

  27. SHI J, Wang X, Tang Y, Meng S, et al
    LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis.
    Gut. 2026 Jan 16:gutjnl-2025-336460. doi: 10.1136/gutjnl-2025-336460.
    >> Share

  28. CHEN K, Ma Y, Huang L, Wu P, et al
    Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics.
    Gut. 2026 Jan 13:gutjnl-2025-335683. doi: 10.1136/gutjnl-2025-335683.
    >> Share

  29. LIU J, Hou X, Li L, Bai W, et al
    KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.
    Gut. 2026 Jan 9:gutjnl-2025-336277. doi: 10.1136/gutjnl-2025-336277.
    >> Share

  30. ZHENG Y, Scheers I, Sandor M, Yi G, et al
    Mutations of Gly277 in CPA1-related chronic pancreatitis: clinical clues for misfolding aetiology.
    Gut. 2026 Jan 6:gutjnl-2025-337733. doi: 10.1136/gutjnl-2025-337733.
    >> Share

  31. WU D, Zhu C, Pan H, Xu H, et al
    Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition.
    Gut. 2026 Jan 6:gutjnl-2025-336235. doi: 10.1136/gutjnl-2025-336235.
    >> Share

  32. GUILABERT L, Cardenas-Jaen K, Vaillo-Rocamora A, Ruiz-Rebollo ML, et al
    Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial).
    Gut. 2026 Jan 2:gutjnl-2025-337154. doi: 10.1136/gutjnl-2025-337154.
    >> Share

    December 2025
  33. LATIF MU, Liu X, Bockelmann A, Huhnold L, et al
    GSK3beta(high)/NFATc1(high) subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair.
    Gut. 2025 Dec 31:gutjnl-2025-336227. doi: 10.1136/gutjnl-2025-336227.
    >> Share

  34. INAMDAR TV, Krannich F, Hesselbarth N, Verma A, et al
    Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis.
    Gut. 2025 Dec 19:gutjnl-2025-335947. doi: 10.1136/gutjnl-2025-335947.
    >> Share

  35. CUI M, Mo S, Bai J, Javed AA, et al
    Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer.
    Gut. 2025 Dec 11:gutjnl-2025-336117. doi: 10.1136/gutjnl-2025-336117.
    >> Share

    November 2025
  36. AMMER-HERRMENAU C, Meier R, Antweiler KL, Asendorf T, et al
    Gut microbiota predict development of postdischarge diabetes mellitus in acute pancreatitis.
    Gut. 2025 Nov 26:gutjnl-2025-336715. doi: 10.1136/gutjnl-2025-336715.
    >> Share

  37. KUSAY Y, Wu D, De Sousa SM, Drogemuller CJ, et al
    Evaluating NGS variant callers in a challenging genomic context with a focus on the PRSS1-PRSS2 locus for hereditary pancreatitis.
    Gut. 2025 Nov 17:gutjnl-2025-336988. doi: 10.1136/gutjnl-2025-336988.
    >> Share

  38. CHARI ST
    Diabetes and pancreatic cancer: a complex and confounding interplay.
    Gut. 2025 Nov 12:gutjnl-2025-336806. doi: 10.1136/gutjnl-2025-336806.
    >> Share

    October 2025
  39. LIN J, Cai W, Kattakayam A, He W, et al
    Pharmacological trials of early intervention in predicted severe acute pancreatitis: implications for therapeutic window and core outcome set.
    Gut. 2025 Oct 29:gutjnl-2025-336884. doi: 10.1136/gutjnl-2025-336884.
    >> Share

  40. HAMADA T, Saito T, Michihata N, Yasunaga H, et al
    Response to: 'Lumen-apposing metal stents for pancreatic fluid collections: has advancing technology encouraged overreach?' by Besim Fazil et al.
    Gut. 2025 Oct 15:gutjnl-2025-337023. doi: 10.1136/gutjnl-2025-337023.
    >> Share

  41. ZHONG J, O'Brien A, Patel MB, Eiser D, et al
    Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma.
    Gut. 2025 Oct 8:gutjnl-2025-335152. doi: 10.1136/gutjnl-2025-335152.
    >> Share

    September 2025
  42. TAN JT, Mao X, Lui DT, Li C, et al
    Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort study.
    Gut. 2025 Sep 18:gutjnl-2025-335837. doi: 10.1136/gutjnl-2025-335837.
    >> Share

  43. AGARGUN BF, Cavus B, Cifcibasi Ormeci A, Demir K, et al
    Lumen-apposing metal stents for pancreatic fluid collections: has advancing technology encouraged over-reach?
    Gut. 2025 Sep 18:gutjnl-2025-336668. doi: 10.1136/gutjnl-2025-336668.
    >> Share

    August 2025
  44. PISEDDU I, Mayerle J, Mahajan UM, Boehmer DFR, et al
    The dual role of IgG4 in immunity: bridging pathophysiology and therapeutic applications.
    Gut. 2025;74:1528-1538.
    >> Share

    July 2025
  45. HAMADA T, Michihata N, Saito T, Kimura Y, et al
    Real-world impact of implementing lumen-apposing metal stents for pancreatic fluid collections: a nationwide Japanese study.
    Gut. 2025 Jul 30:gutjnl-2025-335067. doi: 10.1136/gutjnl-2025-335067.
    >> Share


  46. Correction: pancreatic STAT5 activation promotes KrasG12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer.
    Gut. 2025 Jul 2:gutjnl-2024-332225corr1. doi: 10.1136/gutjnl-2024-332225.
    >> Share

    June 2025
  47. HARLE A, Kleger A
    Early metabolic fate commitment in pancreatic neoplastic precursors.
    Gut. 2025 Jun 4:gutjnl-2025-335439. doi: 10.1136/gutjnl-2025-335439.
    >> Share

  48. YANG J, Yu X, Xiao M, Xu H, et al
    Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer.
    Gut. 2025 Jun 4:gutjnl-2024-334361. doi: 10.1136/gutjnl-2024-334361.
    >> Share

    April 2025
  49. HUANG L, Feng Z, Yang W, Zhu Y, et al
    Parecoxib sequential with imrecoxib for occurrence and remission of severe acute pancreatitis: a multicentre, double-blind, randomised, placebo-controlled trial.
    Gut. 2025 Apr 29:gutjnl-2024-334038. doi: 10.1136/gutjnl-2024-334038.
    >> Share

  50. CHEN Y, Ballaro R, Sans M, Thege FI, et al
    Long-chain sulfatide enrichment is an actionable metabolic vulnerability in intraductal papillary mucinous neoplasm (IPMN)-associated pancreatic cancers.
    Gut. 2025 Apr 23:gutjnl-2025-335220. doi: 10.1136/gutjnl-2025-335220.
    >> Share

  51. BODAS C, Felipe I, Chanez B, Lafarga M, et al
    A Common CTRB misfolding variant associated with pancreatic cancer risk causes ER stress and inflammation in mice.
    Gut. 2025 Apr 19:gutjnl-2024-333406. doi: 10.1136/gutjnl-2024-333406.
    >> Share

  52. WU H, Gao SZ, Yin LD, Wang YH, et al
    Germline mutations and pancreatic cancer risk in chronic pancreatitis.
    Gut. 2025 Apr 5:gutjnl-2024-334277. doi: 10.1136/gutjnl-2024-334277.
    >> Share

    March 2025
  53. PERRI G, Marchegiani G
    Introducing 'borderline observable' intraductal papillary mucinous neoplasms: between pancreatic cancer risk and discontinuation of extended surveillance.
    Gut. 2025 Mar 26:gutjnl-2025-334807. doi: 10.1136/gutjnl-2025-334807.
    >> Share

  54. SUN X, Cai W, Li H, Gao C, et al
    Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling.
    Gut. 2025 Mar 23:gutjnl-2024-333638. doi: 10.1136/gutjnl-2024-333638.
    >> Share

  55. COTE GA
    Rectal non-steroidal anti-inflammatory drugs and post-ERCP pancreatitis: it is time for the next chapter in prophylaxis.
    Gut. 2025 Mar 23:gutjnl-2025-334989. doi: 10.1136/gutjnl-2025-334989.
    >> Share

  56. KANG X, Xia M, Wang J, Wang X, et al
    Rectal diclofenac versus indomethacin for prevention of post-ERCP pancreatitis (DIPPP): a multicentre, double-blind, randomised, controlled trial.
    Gut. 2025 Mar 20:gutjnl-2024-334466. doi: 10.1136/gutjnl-2024-334466.
    >> Share

    January 2025
  57. EKSTROM TL, Rosok RM, Abdelrahman AM, Parassiadis C, et al
    Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer.
    Gut. 2025 Jan 30:gutjnl-2024-334374. doi: 10.1136/gutjnl-2024-334374.
    >> Share

  58. HAMADA T, Oyama H, Nevo D, Tange S, et al
    Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance: a prospective longitudinal cohort study.
    Gut. 2025 Jan 27:gutjnl-2024-333259. doi: 10.1136/gutjnl-2024-333259.
    >> Share

  59. ZHANG S, Deng S, Liu J, Liu S, et al
    Targeting MXD1 sensitises pancreatic cancer to trametinib.
    Gut. 2025 Jan 16:gutjnl-2024-333408. doi: 10.1136/gutjnl-2024-333408.
    >> Share

  60. RUSSELL SN, Demetriou C, Valenzano G, Evans A, et al
    Induction of macrophage efferocytosis in pancreatic cancer via PI3Kgamma inhibition and radiotherapy promotes tumour control.
    Gut. 2025 Jan 9:gutjnl-2024-333492. doi: 10.1136/gutjnl-2024-333492.
    >> Share

  61. TAN JT, Mao X, Cheng HM, Seto WK, et al
    Aspirin is associated with lower risk of pancreatic cancer and cancer-related mortality in patients with diabetes mellitus.
    Gut. 2025 Jan 2:gutjnl-2024-333329. doi: 10.1136/gutjnl-2024-333329.
    >> Share

    December 2024
  62. MASSON E, Vedie AL, Maire F, Godet T, et al
    Frequency of de novo PRSS1 pathogenic variants in a French cohort of idiopathic pancreatitis.
    Gut. 2024 Dec 31:gutjnl-2024-333908. doi: 10.1136/gutjnl-2024-333908.
    >> Share

  63. HOLLENBACH M, Heise C, Abou-Ali E, Gulla A, et al
    Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis.
    Gut. 2024 Dec 12:gutjnl-2022-327996. doi: 10.1136/gutjnl-2022-327996.
    >> Share


  64. Correction: The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells.
    Gut. 2024;74:e11.
    >> Share

    November 2024
  65. XIAO M, Tang R, Pan H, Yang J, et al
    TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality.
    Gut. 2024 Nov 5:gutjnl-2024-332782. doi: 10.1136/gutjnl-2024-332782.
    >> Share

    October 2024
  66. ESPINET E, Natoli G
    Leveraging the tug-of-war with genomic retroelements to enhance immunotherapy of pancreatic cancer.
    Gut. 2024 Oct 22:gutjnl-2024-333702. doi: 10.1136/gutjnl-2024-333702.
    >> Share

  67. ONNEKINK AM, Gorris M, Bekkali NL, Bos P, et al
    Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial.
    Gut. 2024 Oct 10:gutjnl-2024-332695. doi: 10.1136/gutjnl-2024-332695.
    >> Share

    September 2024
  68. SANDOR M, Scheers I, Masamune A, Witt H, et al
    AlphaMissense versus laboratory-based pathogenicity prediction of 13 novel missense CPA1 variants from pancreatitis cases.
    Gut. 2024 Sep 10:gutjnl-2024-333697. doi: 10.1136/gutjnl-2024-333697.
    >> Share


  69. Correction: Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma.
    Gut. 2024;73:e21.
    >> Share

  70. COTE GA, Elmunzer BJ, Nitchie H, Kwon RS, et al
    Sphincterotomy for biliary sphincter of Oddi disorder and idiopathic acute recurrent pancreatitis: the RESPOnD longitudinal cohort.
    Gut. 2024 Sep 7:gutjnl-2024-332686. doi: 10.1136/gutjnl-2024-332686.
    >> Share

    August 2024
  71. TANG Y, Tang S, Yang W, Zhang Z, et al
    MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer.
    Gut. 2024 Aug 31:gutjnl-2024-332350. doi: 10.1136/gutjnl-2024-332350.
    >> Share

  72. ZHOU T, Hou X, Yan J, Li L, et al
    CD64(+) fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8(+) T cells.
    Gut. 2024 Aug 30:gutjnl-2024-332371. doi: 10.1136/gutjnl-2024-332371.
    >> Share

    July 2024
  73. ZUO X, Wang L, Liu Y, Wang H, et al
    Dysregulated KLF4 expression plays a pivotal role in the pathogenesis of pancreatic intraductal papillary mucinous neoplasms.
    Gut. 2024 Jul 5:gutjnl-2024-332255. doi: 10.1136/gutjnl-2024-332255.
    >> Share

  74. KAMAR N, Marion O, Abravanel F, Esposito L, et al
    Porcine-derived pancreatic enzyme replacement therapy: a cause of hepatitis E virus transmission?
    Gut. 2024 Jul 2:gutjnl-2024-332744. doi: 10.1136/gutjnl-2024-332744.
    >> Share

  75. LIN Y, Pu S, Wang J, Wan Y, et al
    Pancreatic STAT5 activation promotes Kras(G12D)-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer.
    Gut. 2024 Jul 1:gutjnl-2024-332225. doi: 10.1136/gutjnl-2024-332225.
    >> Share

    June 2024
  76. SHEN F, Zhao H, Deng M, Tu M, et al
    Familial pancreatitis associated with a splice-site variant in CPA1.
    Gut. 2024 Jun 18:gutjnl-2024-332845. doi: 10.1136/gutjnl-2024-332845.
    >> Share

  77. ZHOU J, Liu K, Pan Q
    Porcine-derived pancreatic enzyme replacement therapy linking to chronic hepatitis E: broad implications.
    Gut. 2024 Jun 12:gutjnl-2024-332975. doi: 10.1136/gutjnl-2024-332975.
    >> Share

  78. BRICHKINA A, Ems M, Suezov R, Singh R, et al
    DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer.
    Gut. 2024 Jun 4:gutjnl-2023-331854. doi: 10.1136/gutjnl-2023-331854.
    >> Share

    May 2024
  79. FRERICKS N, Kinast V, Steinmann E
    Potential risk of porcine-derived pancreatic enzyme medication for the cross-species transmission of hepatitis E virus.
    Gut. 2024 May 31:gutjnl-2024-332577. doi: 10.1136/gutjnl-2024-332577.
    >> Share

  80. VOGT M, Dudvarski Stankovic N, Cruz Garcia Y, Hofstetter J, et al
    Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2.
    Gut. 2024 May 31:gutjnl-2023-331519. doi: 10.1136/gutjnl-2023-331519.
    >> Share

  81. BERKE G, Sahin-Toth M
    Intron-mediated enhancement of SPINK1 expression for pancreatitis therapy.
    Gut. 2024 May 16:gutjnl-2024-332818. doi: 10.1136/gutjnl-2024-332818.
    >> Share

  82. LOPEZ-GIL JC, Garcia-Silva S, Ruiz-Canas L, Navarro D, et al
    The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells.
    Gut. 2024 May 16:gutjnl-2023-330995. doi: 10.1136/gutjnl-2023-330995.
    >> Share

    April 2024
  83. THORNTON CS, Waddell BJ, Congly SE, Svishchuk J, et al
    Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients.
    Gut. 2024 Apr 15:gutjnl-2023-330602. doi: 10.1136/gutjnl-2023-330602.
    >> Share


  84. Correction: Identification of c-FLIPL and c-FLIPS as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells.
    Gut. 2024;73:e8.
    >> Share

    March 2024
  85. WANG YC, Mao XT, Sun C, Wang YH, et al
    Pancreas-directed AAV8-hSPINK1 gene therapy safely and effectively protects against pancreatitis in mice.
    Gut. 2024 Mar 29:gutjnl-2023-330788. doi: 10.1136/gutjnl-2023-330788.
    >> Share

  86. GUNJAN D, Mahapatra SJ, Garg PK
    Is acute necrotising pancreatitis a chronic disease?
    Gut. 2024 Mar 26:gutjnl-2024-331915. doi: 10.1136/gutjnl-2024-331915.
    >> Share

  87. AMMER-HERRMENAU C, Neesse A
    Response to: short-chain fatty acids in patients with severe acute pancreatitis: friend or foe?
    Gut. 2024 Mar 7:gutjnl-2024-332236. doi: 10.1136/gutjnl-2024-332236.
    >> Share

  88. PUST MM, Rocha Castellanos DM, Rzasa K, Dame A, et al
    Absence of a pancreatic microbiome in intraductal papillary mucinous neoplasm.
    Gut. 2024 Mar 1:gutjnl-2023-331012. doi: 10.1136/gutjnl-2023-331012.
    >> Share

    February 2024
  89. VAN DEN BERG FF, Besselink MG, van Santvoort H
    Short-chain fatty acids in patients with severe acute pancreatitis: friend or foe?
    Gut. 2024 Feb 15:gutjnl-2024-332129. doi: 10.1136/gutjnl-2024-332129.
    >> Share

    January 2024
  90. HOLLEMANS RA, Timmerhuis HC, Besselink MG, Bouwense SAW, et al
    Long-term follow-up study of necrotising pancreatitis: interventions, complications and quality of life.
    Gut. 2024 Jan 24:gutjnl-2023-329735. doi: 10.1136/gutjnl-2023-329735.
    >> Share

  91. TONELLI C, Yordanov GN, Hao Y, Deschenes A, et al
    A mucus production programme promotes classical pancreatic ductal adenocarcinoma.
    Gut. 2024 Jan 23:gutjnl-2023-329839. doi: 10.1136/gutjnl-2023-329839.
    >> Share

  92. SABA E, Farhat M, Daoud A, Khashan A, et al
    Oral bacteria accelerate pancreatic cancer development in mice.
    Gut. 2024 Jan 17:gutjnl-2023-330941. doi: 10.1136/gutjnl-2023-330941.
    >> Share

  93. KWAN MC, Pitman MB, Fernandez-Del Castillo C, Zhang ML, et al
    Revisiting the performance of cyst fluid carcinoembryonic antigen as a diagnostic marker for pancreatic mucinous cysts: a comprehensive 20-year institutional review.
    Gut. 2024 Jan 9:gutjnl-2023-331138. doi: 10.1136/gutjnl-2023-331138.
    >> Share

    December 2023
  94. AMMER-HERRMENAU C, Antweiler KL, Asendorf T, Beyer G, et al
    Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitis.
    Gut. 2023 Dec 21:gutjnl-2023-330987. doi: 10.1136/gutjnl-2023-330987.
    >> Share

  95. BEN-AMI R, Wang QL, Zhang J, Supplee JG, et al
    Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer.
    Gut. 2023 Dec 13:gutjnl-2023-331074. doi: 10.1136/gutjnl-2023-331074.
    >> Share

  96. HANNEMANN A, Mayerle J, Beyer G
    Response to: Correspondence on 'Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: still needed further discussion' by Wang et al.
    Gut. 2023 Dec 2:gutjnl-2023-331525. doi: 10.1136/gutjnl-2023-331525.
    >> Share

    October 2023
  97. SANDOR M, Sahin-Toth M
    Functional predictors of pathogenicity of missense CPA1 variants in chronic pancreatitis.
    Gut. 2023 Oct 19:gutjnl-2023-331105. doi: 10.1136/gutjnl-2023-331105.
    >> Share

  98. WANG F, Peng L, Liu Y
    Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: still needed further discussion.
    Gut. 2023 Oct 10:gutjnl-2023-331163. doi: 10.1136/gutjnl-2023-331163.
    >> Share

  99. MICHL P, Roth L
    Female advantage in neoadjuvant pancreatic cancer therapy: is it down to macrophages?
    Gut. 2023 Oct 9:gutjnl-2023-330830. doi: 10.1136/gutjnl-2023-330830.
    >> Share

    September 2023
  100. VAN EIJCK CWF, Mustafa DAM, Vadgama D, de Miranda NFCC, et al
    Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer.
    Gut. 2023 Sep 14:gutjnl-2023-330480. doi: 10.1136/gutjnl-2023-330480.
    >> Share

  101. WU Y, Seufert I, Al-Shaheri FN, Kurilov R, et al
    DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma.
    Gut. 2023 Sep 14:gutjnl-2023-330155. doi: 10.1136/gutjnl-2023-330155.
    >> Share

  102. KARSTENSEN JG, Novovic S, Schmidt PN
    Tailoring treatment to the circumstance: reasoning behind metal versus plastic drainage of pancreatic collections - authors' reply.
    Gut. 2023 Sep 12:gutjnl-2023-330948. doi: 10.1136/gutjnl-2023-330948.
    >> Share

    August 2023
  103. LIU X, Tang R, Xu J, Tan Z, et al
    CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-kappaB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.
    Gut. 2023 Aug 4:gutjnl-2022-329349. doi: 10.1136/gutjnl-2022-329349.
    >> Share

    July 2023
  104. VANELLA G, Bronswijk M, Van der Merwe SW, Arcidiacono PG, et al
    Tailoring treatment to the circumstance: reasoning behind metal versus plastic drainage of pancreatic collections.
    Gut. 2023 Jul 31:gutjnl-2023-330442. doi: 10.1136/gutjnl-2023-330442.
    >> Share

    June 2023
  105. BLANCO-GOMEZ A, Jorgensen C
    FAK scaffolds immune escape in pancreatic cancer.
    Gut. 2023 Jun 6:gutjnl-2023-330049. doi: 10.1136/gutjnl-2023-330049.
    >> Share

  106. SAMANTA J, Dhar J
    Plastic is as good as metal: is the 'debris clearance' debate for walled-off necrosis drainage finally over?
    Gut. 2023;72:1223-1224.
    >> Share

    May 2023
  107. KINKER GS, Vitiello GAF, Diniz AB, Cabral-Piccin MP, et al
    Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas.
    Gut. 2023 May 25:gutjnl-2022-328697. doi: 10.1136/gutjnl-2022-328697.
    >> Share

    April 2023
  108. ZORNIAK M, Sirtl S, Beyer G, Mahajan UM, et al
    Consensus definition of sludge and microlithiasis as a possible cause of pancreatitis.
    Gut. 2023 Apr 18:gutjnl-2022-327955. doi: 10.1136/gutjnl-2022-327955.
    >> Share

  109. BANG JY, Jhala N, Seth A, Krall K, et al
    Standardisation of EUS-guided FNB technique for molecular profiling in pancreatic cancer: results of a randomised trial.
    Gut. 2023 Apr 11:gutjnl-2023-329495. doi: 10.1136/gutjnl-2023-329495.
    >> Share

  110. RAPETTI-MAUSS R, Nigri J, Berenguier C, Finetti P, et al
    SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer.
    Gut. 2023;72:722-735.
    >> Share

    March 2023
  111. CANEL M, Slawinska AD, Lonergan DW, Kallor AA, et al
    FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
    Gut. 2023 Mar 28:gutjnl-2022-327927. doi: 10.1136/gutjnl-2022-327927.
    >> Share

  112. HAMDAN FH, Abdelrahman AM, Kutschat AP, Wang X, et al
    Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer.
    Gut. 2023 Mar 8:gutjnl-2022-328154. doi: 10.1136/gutjnl-2022-328154.
    >> Share

    February 2023
  113. HALLENSLEBEN ND, Stassen PMC, Schepers NJ, Besselink MG, et al
    Patient selection for urgent endoscopic retrograde cholangio-pancreatography by endoscopic ultrasound in predicted severe acute biliary pancreatitis (APEC-2): a multicentre prospective study.
    Gut. 2023 Feb 27:gutjnl-2022-328258. doi: 10.1136/gutjnl-2022-328258.
    >> Share

  114. LIU J, Bai W, Zhou T, Xie Y, et al
    SDCBP promotes pancreatic cancer progression by preventing YAP1 from beta-TrCP-mediated proteasomal degradation.
    Gut. 2023 Feb 24:gutjnl-2022-327492. doi: 10.1136/gutjnl-2022-327492.
    >> Share

  115. BEYER G, Kasprowicz F, Hannemann A, Aghdassi A, et al
    Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: a population-based, cross-sectional cohort study.
    Gut. 2023 Feb 24:gutjnl-2021-326106. doi: 10.1136/gutjnl-2021-326106.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016